Matinas reports positive MAT2203 compassionate use data: 12 of 15 patients improved, all completers resolved.

Matinas BioPharma Holdings, Inc.

19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.
12 of 15 patients had complete clinical resolution or objective improvement in infection markers.
All 5 patients who completed full treatment (2 weeks to 1 year) had complete resolution with no relapse.
All patients who transitioned from AmBisome due to renal toxicity saw return to baseline renal function.
Patients treated at 9 major institutions including Johns Hopkins, NIH, Memorial Sloan Kettering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.